Tyrosine Protein Kinase CSK - Pipeline Review, H2 2019
Tyrosine Protein Kinase CSK - Pipeline Review, H2 2019
SUMMARY
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Tyrosine-protein kinase CSK also known as C-terminal Src kinase is an enzyme that, in humans, is encoded by the CSK gene. It plays an important role in the regulation of cell growth, differentiation, migration and immune response. It phosphorylates tyrosine residues located in the C-terminal tails of Src-family kinases (SFKs). To inhibit SFKs, CSK is recruited to the plasma membrane via binding to transmembrane proteins or adapter proteins located near the plasma membrane. It suppresses signaling by various surface receptors including T-cell receptor (TCR) and B-cell receptor (BCR).
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) pipeline Target constitutes close to 11 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II and Phase I stages are 1, 2, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.
Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Dermatology, Gastrointestinal, Immunology, Infectious Disease, Respiratory and Toxicology which include indications Breast Cancer, Colon Cancer, High-Grade Glioma, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Actinic (Solar) Keratosis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Amyotrophic Lateral Sclerosis, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Angiosarcoma, Arrhythmias, Asthma, B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Cervical Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Epithelial Ovarian Cancer, Epstein-Barr Virus (HHV-4) Infections, Esophageal Squamous Cell Carcinoma (ESCC), Ewing Sarcoma, Fallopian Tube Cancer, Fibrosarcoma, Gallbladder Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Leiomyosarcoma, Liposarcoma, Liver Fibrosis, Lung Adenocarcinoma, Lymphoma, Melanoma, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Mild Cognitive Impairment, Myocardial Infarction, Nasopharyngeal Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Prostate Cancer, Psoriasis, Radiation Injury, Recurrent Glioblastoma Multiforme (GBM), Recurrent Malignant Glioma, Renal Cell Carcinoma, Rhabdomyosarcoma, Skin Cancer, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Synovial Sarcoma, T-Cell Lymphomas, Thymoma (Thymic Epithelial Tumor), Thyroid Cancer and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
The latest report Tyrosine Protein Kinase CSK - Pipeline Review, H2 2019, outlays comprehensive information on the Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Tyrosine-protein kinase CSK also known as C-terminal Src kinase is an enzyme that, in humans, is encoded by the CSK gene. It plays an important role in the regulation of cell growth, differentiation, migration and immune response. It phosphorylates tyrosine residues located in the C-terminal tails of Src-family kinases (SFKs). To inhibit SFKs, CSK is recruited to the plasma membrane via binding to transmembrane proteins or adapter proteins located near the plasma membrane. It suppresses signaling by various surface receptors including T-cell receptor (TCR) and B-cell receptor (BCR).
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) pipeline Target constitutes close to 11 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II and Phase I stages are 1, 2, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.
Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Dermatology, Gastrointestinal, Immunology, Infectious Disease, Respiratory and Toxicology which include indications Breast Cancer, Colon Cancer, High-Grade Glioma, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Actinic (Solar) Keratosis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Amyotrophic Lateral Sclerosis, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Angiosarcoma, Arrhythmias, Asthma, B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Cervical Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Epithelial Ovarian Cancer, Epstein-Barr Virus (HHV-4) Infections, Esophageal Squamous Cell Carcinoma (ESCC), Ewing Sarcoma, Fallopian Tube Cancer, Fibrosarcoma, Gallbladder Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Leiomyosarcoma, Liposarcoma, Liver Fibrosis, Lung Adenocarcinoma, Lymphoma, Melanoma, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Mild Cognitive Impairment, Myocardial Infarction, Nasopharyngeal Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Prostate Cancer, Psoriasis, Radiation Injury, Recurrent Glioblastoma Multiforme (GBM), Recurrent Malignant Glioma, Renal Cell Carcinoma, Rhabdomyosarcoma, Skin Cancer, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Synovial Sarcoma, T-Cell Lymphomas, Thymoma (Thymic Epithelial Tumor), Thyroid Cancer and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
The latest report Tyrosine Protein Kinase CSK - Pipeline Review, H2 2019, outlays comprehensive information on the Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Advenchen Laboratories LLC
Athenex Inc
Pfizer Inc
Pulmatrix Inc
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Drug Profiles
apatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bosutinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eCF-506 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KX-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PUR-1800 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit C Src Kinase for Colon Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CSK for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Src Tyrosine Kinase for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tirbanibulin mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UM-164 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Oct 28, 2019: Athenex announces progress update from partner Almirall on Tirbanibulin Ointment
Sep 29, 2019: Elevar announces results from the ANGEL trial, a study of Monotherapy Rivoceranib (Apatinib) in Late-stage Gastric Cancer patients
Sep 11, 2019: Athenex announces initiation of phase I clinical study in china of KX2-36 oral by partner Guangzhou Xiangxue pharmaceutical
Aug 23, 2019: HLB wins FDA nod for P2 trial on rivoceranib in adenoid cystic carcinoma
Aug 06, 2019: HLB to seek pre-NDA meeting with FDA for rivoceranib
Jun 27, 2019: LSK BioPharma announces preliminary review of top-line results from ANGEL Study
Jun 06, 2019: Athenex and PharmaEssentia announce positive early signals of clinical activity of KX2-391 (INN: tirbanibulin) in patients with Psoriasis
Apr 08, 2019: LSK BioPharma and Jiangsu Hengrui Medicine announce FDA clearance to initiate a phase 3 clinical trial in advanced Hepatocellular Carcinoma
Mar 04, 2019: Athenex announces positive topline results from two phase III studies of KX2-391 ointment 1% featured in late breaker program at the 2019 American Academy of Dermatology Annual Meeting
Feb 25, 2019: Athenex to host conference call with key opinion leader following oral presentation of phase III results of KX2-391 ointment in the treatment of actinic keratosis at the American Academy of Dermatology Annual Meeting
Feb 12, 2019: LSKB Announces that the ANGEL Study Has Reached its Primary Completion Date
Feb 12, 2019: Pulmatrix receives US Patent for Inhaled Narrow Spectrum Kinase Inhibitor PUR1800
Feb 04, 2019: Athenex announces late-breaking oral presentation of KX2-391 ointment in two phase III studies at the American Academy of Dermatology Annual Meeting
Oct 29, 2018: LSKB announces completion of enrollment for the ANGEL Study of Rivoceranib (Apatinib) in Gastric Cancer
Sep 17, 2018: Pulmatrix to present pre-clinical data on PUR1800 (RV1162) at the European Respiratory Society International Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Advenchen Laboratories LLC
Athenex Inc
Pfizer Inc
Pulmatrix Inc
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Drug Profiles
apatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bosutinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eCF-506 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KX-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PUR-1800 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit C Src Kinase for Colon Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CSK for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Src Tyrosine Kinase for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tirbanibulin mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UM-164 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Oct 28, 2019: Athenex announces progress update from partner Almirall on Tirbanibulin Ointment
Sep 29, 2019: Elevar announces results from the ANGEL trial, a study of Monotherapy Rivoceranib (Apatinib) in Late-stage Gastric Cancer patients
Sep 11, 2019: Athenex announces initiation of phase I clinical study in china of KX2-36 oral by partner Guangzhou Xiangxue pharmaceutical
Aug 23, 2019: HLB wins FDA nod for P2 trial on rivoceranib in adenoid cystic carcinoma
Aug 06, 2019: HLB to seek pre-NDA meeting with FDA for rivoceranib
Jun 27, 2019: LSK BioPharma announces preliminary review of top-line results from ANGEL Study
Jun 06, 2019: Athenex and PharmaEssentia announce positive early signals of clinical activity of KX2-391 (INN: tirbanibulin) in patients with Psoriasis
Apr 08, 2019: LSK BioPharma and Jiangsu Hengrui Medicine announce FDA clearance to initiate a phase 3 clinical trial in advanced Hepatocellular Carcinoma
Mar 04, 2019: Athenex announces positive topline results from two phase III studies of KX2-391 ointment 1% featured in late breaker program at the 2019 American Academy of Dermatology Annual Meeting
Feb 25, 2019: Athenex to host conference call with key opinion leader following oral presentation of phase III results of KX2-391 ointment in the treatment of actinic keratosis at the American Academy of Dermatology Annual Meeting
Feb 12, 2019: LSKB Announces that the ANGEL Study Has Reached its Primary Completion Date
Feb 12, 2019: Pulmatrix receives US Patent for Inhaled Narrow Spectrum Kinase Inhibitor PUR1800
Feb 04, 2019: Athenex announces late-breaking oral presentation of KX2-391 ointment in two phase III studies at the American Academy of Dermatology Annual Meeting
Oct 29, 2018: LSKB announces completion of enrollment for the ANGEL Study of Rivoceranib (Apatinib) in Gastric Cancer
Sep 17, 2018: Pulmatrix to present pre-clinical data on PUR1800 (RV1162) at the European Respiratory Society International Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Advenchen Laboratories LLC, H2 2019
Pipeline by Athenex Inc, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Pulmatrix Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Advenchen Laboratories LLC, H2 2019
Pipeline by Athenex Inc, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Pulmatrix Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Advenchen Laboratories LLC
Athenex Inc
Pfizer Inc
Pulmatrix Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Advenchen Laboratories LLC
Athenex Inc
Pfizer Inc
Pulmatrix Inc
